Guillain-Barre syndrome following autologous bone marrow transplantation.
The pathogenesis of the Guillain-Barre syndrome (GBS) is felt to involve alterations in cellular and humoral immune responses. We report the case of a 44-year-old female with stage IV breast cancer who developed GBS 2 days after receiving high dose chemotherapy with bone marrow and peripheral progenitor cell support, and granulocyte-macrophage colony stimulating factor (GM-CSF). Her clinical status stabilized with plasmapheresis. This report lends further support to hypotheses regarding cellular immune alterations in the pathogenesis of GBS.
Mudad
R
R
Department of Hematology-Oncology, Duke University Medical Center, Durham, North Carolina 27710.
Hussein
A
A
Peters
W P
WP
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000150:complications / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015409:Mastectomy, Radical; D011129:Polyradiculoneuropathy / Q000209:etiology*
D016178:Granulocyte-Macrophage Colony-Stimulating Factor